Covered recipient · General Payments record
LAURA KYLE BRETT
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2019–2024
$749.07
- Reported across 41 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Education | $160.10 | 14 |
| Food and Beverage | $103.72 | 5 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $146.20 | 13 |
| Ipsen Biopharmaceuticals, Inc | $32.46 | 2 |
| Acrotech Biopharma Inc. | $23.64 | 1 |
| Astellas Pharma US Inc | $22.95 | 1 |
| Myriad Genetic Laboratories, Inc. | $19.64 | 1 |
| ABBVIE INC. | $18.93 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (19)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.93 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103367049 | CMS |
| Acrotech Biopharma Inc. | $23.64 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147104724 | CMS |
| Astellas Pharma US Inc | $22.95 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139432730 | CMS |
| Ipsen Biopharmaceuticals, Inc | $16.23 | 04/16/2024 | Education | Undisputed | 01/23/2026 | 1091966198 | CMS |
| Ipsen Biopharmaceuticals, Inc | $16.23 | 08/20/2024 | Education | Undisputed | 01/23/2026 | 1091966200 | CMS |
| Myriad Genetic Laboratories, Inc. | $19.64 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152528178 | CMS |
| PFIZER INC. | $11.88 | 03/11/2024 | Education | Undisputed | 01/23/2026 | 1130893545 | CMS |
| PFIZER INC. | $14.17 | 05/30/2024 | Education | Undisputed | 01/23/2026 | 1131357761 | CMS |
| PFIZER INC. | $7.98 | 07/16/2024 | Education | Undisputed | 01/23/2026 | 1130923660 | CMS |
| PFIZER INC. | $11.88 | 07/16/2024 | Education | Undisputed | 01/23/2026 | 1130923976 | CMS |
| PFIZER INC. | $7.98 | 11/09/2024 | Education | Undisputed | 01/23/2026 | 1131090069 | CMS |
| PFIZER INC. | $11.88 | 11/11/2024 | Education | Undisputed | 01/23/2026 | 1131025006 | CMS |
| PFIZER INC. | $7.98 | 11/11/2024 | Education | Undisputed | 01/23/2026 | 1131120231 | CMS |
| PFIZER INC. | $18.56 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131176528 | CMS |
| PFIZER INC. | $11.88 | 11/18/2024 | Education | Undisputed | 01/23/2026 | 1131038644 | CMS |
| PFIZER INC. | $14.17 | 11/18/2024 | Education | Undisputed | 01/23/2026 | 1131099200 | CMS |
| PFIZER INC. | $7.98 | 11/18/2024 | Education | Undisputed | 01/23/2026 | 1131145289 | CMS |
| PFIZER INC. | $11.88 | 11/20/2024 | Education | Undisputed | 01/23/2026 | 1131047302 | CMS |
| PFIZER INC. | $7.98 | 11/20/2024 | Education | Undisputed | 01/23/2026 | 1131051009 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.